Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

In vitro-In vivo extrapolation of key transporter activity at the blood-brain barrier.

Trapa PE, Troutman MD, Lau TY, Wager TT, Maurer TS, Patel NC, West MA, Umland JP, Carlo AA, Feng B, Liras JL.

Drug Metab Dispos. 2019 Jan 25. pii: dmd.118.083279. doi: 10.1124/dmd.118.083279. [Epub ahead of print]

2.

Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship.

Fu C, Di L, Han X, Soderstrom C, Snyder M, Troutman MD, Obach RS, Zhang H.

Drug Metab Dispos. 2013 Oct;41(10):1797-804. doi: 10.1124/dmd.113.053082. Epub 2013 Jul 15.

PMID:
23857892
3.

Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design.

Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, Lai Y, Duckworth J, Fenner K, Troutman MD, Obach RS.

Eur J Med Chem. 2012 Nov;57:441-8. doi: 10.1016/j.ejmech.2012.06.043. Epub 2012 Jul 16.

PMID:
22840492
4.

Development of a new permeability assay using low-efflux MDCKII cells.

Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ 3rd, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD.

J Pharm Sci. 2011 Nov;100(11):4974-85. doi: 10.1002/jps.22674. Epub 2011 Jul 15.

PMID:
21766308
5.

Species independence in brain tissue binding using brain homogenates.

Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE.

Drug Metab Dispos. 2011 Jul;39(7):1270-7. doi: 10.1124/dmd.111.038778. Epub 2011 Apr 7.

PMID:
21474681
6.

Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, Will Y.

ACS Chem Neurosci. 2010 Jun 16;1(6):420-34. doi: 10.1021/cn100007x. Epub 2010 Mar 25.

7.

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.

Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.

J Med Chem. 2010 Feb 11;53(3):1098-108. doi: 10.1021/jm901371v.

PMID:
20070106
8.

Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.

Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, Lee CA.

Mol Pharm. 2010 Apr 5;7(2):398-411. doi: 10.1021/mp900174z.

PMID:
20025245
9.

Physicochemical determinants of human renal clearance.

Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.

J Med Chem. 2009 Aug 13;52(15):4844-52. doi: 10.1021/jm900403j.

PMID:
19445515
10.

N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.

Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, Fenner KS, Troutman MD.

J Pharm Sci. 2009 Dec;98(12):4914-27. doi: 10.1002/jps.21756.

PMID:
19373887
11.
12.

High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models.

Hop CE, Cole MJ, Davidson RE, Duignan DB, Federico J, Janiszewski JS, Jenkins K, Krueger S, Lebowitz R, Liston TE, Mitchell W, Snyder M, Steyn SJ, Soglia JR, Taylor C, Troutman MD, Umland J, West M, Whalen KM, Zelesky V, Zhao SX.

Curr Drug Metab. 2008 Nov;9(9):847-53. Review.

PMID:
18991580
13.

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.

Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA.

Clin Pharmacol Ther. 2009 Feb;85(2):173-81. doi: 10.1038/clpt.2008.195. Epub 2008 Nov 5.

PMID:
18987624
14.

Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers.

Faessel HM, Burstein AH, Troutman MD, Willavize SA, Rohrbacher KD, Clark DJ.

Eur J Clin Pharmacol. 2008 Nov;64(11):1101-9. doi: 10.1007/s00228-008-0530-6. Epub 2008 Jul 26.

PMID:
18661125
15.

In silico modeling of nonspecific binding to human liver microsomes.

Gao H, Yao L, Mathieu HW, Zhang Y, Maurer TS, Troutman MD, Scott DO, Ruggeri RB, Lin J.

Drug Metab Dispos. 2008 Oct;36(10):2130-5. doi: 10.1124/dmd.107.020131. Epub 2008 Jul 7.

PMID:
18606744
16.

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.

Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM.

Drug Metab Dispos. 2008 Feb;36(2):268-75. Epub 2007 Oct 25.

PMID:
17962372
17.

Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.

Singleton DH, Boyd H, Steidl-Nichols JV, Deacon M, Groot MJ, Price D, Nettleton DO, Wallace NK, Troutman MD, Williams C, Boyd JG.

J Med Chem. 2007 Jun 28;50(13):2931-41. Epub 2007 May 31.

PMID:
17536794
20.
21.

Phospholipase C-gamma modulates epithelial tight junction permeability through hyperphosphorylation of tight junction proteins.

Ward PD, Klein RR, Troutman MD, Desai S, Thakker DR.

J Biol Chem. 2002 Sep 20;277(38):35760-5. Epub 2002 Jul 5.

Supplemental Content

Loading ...
Support Center